High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of high-dose vitamin C combined with metformin in the treatment of malignant tumors.
Hepatocellular Cancer|Pancreatic Cancer|Gastric Cancer|Colorectal Cancer
DRUG: Vitamin C|DRUG: Metformin
Progression-free survival, Defined as time from first dose of treatment to death from any cause, or even radiological detection/or clinical of disease progression., up to 12 weeks
Overall survival, Defined as time from first dose of treatment until death., up to 12 weeks|Objective response rate, Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1., up to 12 weeks|Disease control rate, Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1., up to 12 weeks|Changes of quality of life, Examination of quality of life by EORTC QLQ-C30 questionnaire every 8 weeks., up to 12 weeks|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0, The number of grade 1-4 and grade 5 (fatal) NCI Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) events during treatment. All patients will be evaluable for toxicity from the time of their first treatment., up to 12 weeks
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of high-dose vitamin C combined with metformin in the treatment of malignant tumors.